2014-03-21 21:22:47 UTC

Gastroenterology Podcast March 2014: Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Chronic Hepatitis C

A phase-3 study in the March issue of Gastroenterology examined the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Dr. Kuemmerle discusses the results with first author Dr. Maria Buti; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Buti M, Agarwal K, Horsmans Y, et al. Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. Gastroenterology 2014; March; 146(3): 744-753
Abstract

 

 

Duration: 14.52m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on Hepatitis C

Building Foundations Among Payers & Providers for Collaborative Care in HCV & HIV

Dec. 7, 2017

In this video, leading experts in HCV, HIV, and managed care engage in a crossfire panel discussion on key challenges, considerations and solutions for improving patient management, and appropriate access to HCV and HIV therapies.

Translating Basic Science Into Clinical Application

Dec. 7, 2017

The CMGH editors summarize five recently accepted studies in four sentences or less.

Experts Update HCV Treatment and Care Guidelines

Nov. 9, 2017

Revision adds newly approved treatments and recommendations for special populations.